Andrea K. Ng
Research Subjects
Research Interests
Andrea K. Ng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Wirth
Peter MacCallum Cancer Centre
1 shared publication Heather A. Jacene
B Department of Radiology , Dana-Farber Cancer Institute/Brigham and Women's Hospital , Boston , MA , USA
1 shared publicationMalika L. Siker
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publicationPeter M. Mauch
D Department of Radiation Oncology , Dana-Farber Cancer Institute/Brigham and Women's Hospital , Boston , MA , USA
1 shared publicationSandy Constine
Strong Memorial Hospital
1 shared publication- Sophia Constance Kamran
Department of Radiation Oncology, Mass General Brigham , 800 Boylston St., 02199 Boston, MA
1 shared publication
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 265-284
Radiation Therapy for Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- 1 January 2024
- Published by Springer Nature
- p. 265-284
Radiation Therapy for Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- 1 June 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 110 (2) , 312-314
Standardizing Professional Title Use at American Society for Radiation Oncology Annual Meetings
- 1 June 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 110 (2) , 312-314
Standardizing Professional Title Use at American Society for Radiation Oncology Annual Meetings
- 1 February 2020
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 34 (1) , 127-142
Hematologic Malignancies
- 1 February 2020
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 34 (1) , 127-142
Hematologic Malignancies
- 22 September 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (6) , 1384-1390
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT assessment and involved-site radiotherapy (ISRT) to 20Gy. Records of 23 patients who met eligibility criteria, treated between 2008 and 2016, were reviewed. PET response after two cycles of ABVD was independently assessed by a nuclear medicine physician. After two cycles of ABVD, 91.3% of patients had a Deauville score of 1-2; 1 patient had a score of 3. Median follow-up was 45.3 months. As of this analysis, all patients are alive without disease. One patient had an out-of-field relapse, yielding a 4-year relapse-free survival rate of 92.9% (95%CI [59.1, 99.0]). Our results showed that with careful patient selection by initial disease characteristics and FDG-PET response to chemotherapy, the use of a more restricted treatment volume of ISRT to 20Gy following ABVDx2 is associated with excellent outcomes.
- 22 September 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (6) , 1384-1390
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT assessment and involved-site radiotherapy (ISRT) to 20Gy. Records of 23 patients who met eligibility criteria, treated between 2008 and 2016, were reviewed. PET response after two cycles of ABVD was independently assessed by a nuclear medicine physician. After two cycles of ABVD, 91.3% of patients had a Deauville score of 1-2; 1 patient had a score of 3. Median follow-up was 45.3 months. As of this analysis, all patients are alive without disease. One patient had an out-of-field relapse, yielding a 4-year relapse-free survival rate of 92.9% (95%CI [59.1, 99.0]). Our results showed that with careful patient selection by initial disease characteristics and FDG-PET response to chemotherapy, the use of a more restricted treatment volume of ISRT to 20Gy following ABVDx2 is associated with excellent outcomes.